敗血症診断製品と市場動向

敗血症の診断と治療は、医療現場が現在直面している最大の課題の1つです。米国では、年間約170万件の敗血症が発生しており、約27万人が死亡しています。敗血症は、米国の病院で治療される疾患の中で最も費用のかかるものとなっています。

敗血症の診断は簡単ではありません。血液培養分析は、時間がかかり労力も要するという事実にもかかわらず、いまだに標準的検査法となっています。敗血症の複雑さや他の感染症との併発により、この分野は非常に幅広い製品と技術で構成されています。

当レポートでは、敗血症診断の技術・市場動向について分析し、現在の主な検査方法とその利点・欠点、現在上市されている製品の概略、他の感染症 (特にCOVID-19) との併発の場合、といった情報を取りまとめてお届けいたします。

目次

第1章 エグゼクティブサマリー

• 概要
• 専門的なガイドラインと定義
  • SIRS基準と敗血症-1
  • 敗血症-2
  • 敗血症-3
  • シーケンシャル (敗血症関連) 臓器不全 (SOFA) 、qSOFA
• 市場の考慮事項

第2章 宿主反応検査

• プロカルシトニン (PCT)
  • 利点
  • 短所
• CRP
  • 利点
  • 短所
• 乳酸
• サイトカイン
• RNA、MRNA、MICRORNA (MIRNA)
• PROADRENOMEDULLIN (PROADM)
• D-ダイマー
• マルチマーカー・アプローチ

第3章 病原体の検出／識別および抗菌薬感受性試験 (AST)

• マルチプレックス分子アッセイ
  • 敗血症に使用されるマルチプレックス分子アッセイ
• 質量分析：人気の高い手法
  • 微生物識別／AST (抗菌物質感受性検査) 向け製品の幅広い選択肢

第4章 新型コロナウイルス感染症 (COVID-19) と敗血症

• COVID-19と敗血症との重複

第5章 市場における主要な敗血症関連製品

The diagnosis and treatment of sepsis is one of the biggest challenges facing healthcare currently. In the United States, there are around 1.7 million cases of sepsis per year, resulting in approximately 270,000 deaths. Overall, the costs associated with sepsis make it the most expensive condition treated in US hospitals.

This report provides comprehensive information on products in the sepsis market, as well as:

• Sepsis Detection Practice Trends

• Sepsis Related Biomarkers: Advantages and Disadvantages

• Markets for Sepsis-Related Testing

• Mass Spectrometry and Sepsis

• COVID-19 and Sepsis

• Sepsis Testing Products on the Market (Grouped by Technology, POC, AST, Culture/ID, NGS, Host Response, amp-free isothermal or alt, Approval Status)

The diagnosis of sepsis is not straightforward. Blood culture analysis has remained a gold standard, despite the fact that it is typically slow and labor-intensive. The complexity of sepsis and the overlap with infectious diseases causes this field to comprise a very large range of products and technologies. This report takes into consideration the status of sepsis as a disease present within many other diseases. A special section on COVID-19 is included.

This report does cover many of the systems and products that diagnose infectious diseases, with an emphasis on rapid or multiplexed tests; but it does not provide a comprehensive breakdown of products for infectious disease detection. There is also a variety of other tests that are only touched upon, which also may be run depending on the appropriate action-blood gases, bilirubin, creatinine, platelets, etc.

Products from the following companies are considered in this report:

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

• OVERVIEW

• PROFESSIONAL GUIDELINES AND DEFINITIONS
  • SIRS Criteria and Sepsis-1
  • Sepsis-2
  • Sepsis-3
  • Sequential (Sepsis-related) Organ Failure (SOFA), qSOFA

• MARKET CONSIDERATIONS
  • Figure 1-1: Approximate Sepsis-Related Test Markets (CRP Market for All Applications, PCT Test Market for All Applications, Sepis-Purposed HAIs)

CHAPTER 2: TESTING OF HOST RESPONSE

• Table 2-1: Top Biomarkers Used in Sepsis

• PROCALCITONIN (PCT)
  • Advantages
  • Disadvantages

• CRP
  • Advantages
  • Disadvantages

• LACTATE
• CYTOKINES
• RNA, MRNA, MICRORNA (MIRNA)
• PROADRENOMEDULLIN (PROADM)
• D-DIMER
• MULTI-MARKER APPROACHES

CHAPTER 3: PATHOGEN DETECTION/ IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TESTING

• MULTIPLEX MOLECULAR ASSAYS
  • Multiplex Molecular Assays Used for Sepsis
    • Table 3-1: Multiplex Molecular Assays Used for Sepsis

• MASS SPECTROMETRY ACHIEVING POPULARITY
  • Wide Selection of Products for Microbe ID, AST
    • Table 3-2: Selected Mass Spectrometry Products Used for Microbial ID and AST
    • Table 3-3: Systems and Products for Bacterial Culture, Staining, Incubation

CHAPTER 4: COVID-19 AND SEPSIS

• COVID-19 AND OVERLAP WITH SEPSIS

CHAPTER 5: MAJOR SEPSIS-RELATED PRODUCTS ON THE MARKET

• Table 5-1: Sepsis Products on the Market